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Novel therapeutic approaches are urgently required
for multiple myeloma (MM). We used a phenotypic
screening approach using co-cultures of MM cells
with bone marrow stromal cells to identify com-
pounds that overcome stromal resistance. One
such compound, BRD9876, displayed selectivity
over normal hematopoietic progenitors and was
discovered to be an unusual ATP non-competitive ki-
nesin-5 (Eg5) inhibitor. A novel mutation caused
resistance, suggesting a binding site distinct from
known Eg5 inhibitors, and BRD9876 inhibited only
microtubule-bound Eg5. Eg5 phosphorylation, which
increases microtubule binding, uniquely enhanced
BRD9876 activity. MM cells have greater phosphory-
lated Eg5 than hematopoietic cells, consistent with
increased vulnerability specifically to BRD9876’s
mode of action. Thus, differences in Eg5-microtubule
binding between malignant and normal blood cells
may be exploited to treat multiple myeloma. Addi-
tional steps are required for further therapeutic
development, but our results indicate that unbiased
chemical biology approaches can identify therapeu-Cetic strategies unanticipated by prior knowledge of
protein targets.INTRODUCTION
Multiple myeloma (MM) is an incurable malignancy that caused
more than 80,000 deaths in 2012 worldwide (Ferlay et al.,
2013). Novel therapeutic approaches are desperately needed,
but target-based drug development against this disease is chal-
lenging due to complex genomic alterations including multiple
driver mutations even within the same individual (Lohr et al.,
2014). An alternative phenotypic approach to therapeutic dis-
covery is to define a cellular phenotype representative of the
disease and to use small-molecule screening to discover simul-
taneously relevant therapeutic targets and lead compounds. The
success of this general approach is shown by the observation
that the majority of first-in-class drugs approved by the US
Food and Drug Administration (FDA) between 1999 and 2008
came from phenotypic approaches despite the dominance of
target-based drug discovery during that period (Swinney and
Anthony, 2011). In MM, novel therapeutic discovery has oc-
curred largely using the phenotypic approach. Lactacystin, a
natural product with phenotypic effects in cancer cells, was
used to discover that the proteasome could be targeted selec-
tively by engaging a catalytic b-subunit N-terminal threoninell Reports 10, 755–770, February 10, 2015 ª2015 The Authors 755
Figure 1. Assays to Identify Small-Molecule Inhibitors of Multiple Myeloma within Its Stromal Niche
(A) Different Calcein AM staining characteristics of multiple myeloma (MM) cells and stromal cells. Primary bone marrow stroma cells (stroma) were either grown
alone (bottom) or co-cultured with primary CD138+MM (top) and stained with the vital dye Calcein AM. Differences in cell shape, size, and fluorescence intensity
were used to distinguish the two cell types. The scale bar represents 500 mm.
(B) Stroma dependence of primary MM and MOLP5 cells. Top: primary CD138+ MM cells were cultured with stroma (left) or alone in media (right) in 384-well
plates and then stained with Calcein AM and imaged. Bottom: GFP-labeled MOLP5 cells were similar grown with stroma (left) or alone (right) for 5 days and then
imaged. The scale bar represents 500 mm.
(C) Enhanced growth of MM1S and INA6 cells with stroma. Left: GFP-labeled MM1S cells were cultured with stromal cells or alone for 5 days and then GFP+ cells
were counted using the MetaXpress software (Molecular Devices). Right: GFP-labeled INA6 cells were cultured with stroma, in media with IL6, or in media alone
for 5 days and then quantified by imaging. Data are averages (avg) ± SEM (n = 14).
(legend continued on next page)
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(Fenteany et al., 1995). This knowledge accelerated the discov-
ery and development of bortezomib from previously unselective
peptide aldehydes (Adams et al., 1998), and subsequently,
bortezomib transformed the treatment of MM (Richardson
et al., 2005). The development of thalidomide and its analogs
against MM also followed phenotypic observations of thalido-
mide’s effects on angiogenesis and immune function (Bartlett
et al., 2004). Based on these encouraging precedents, we under-
took a phenotypic screening approach to systematically dis-
cover compounds that uncover new therapeutic strategies
against MM.
In 95% of MM cases, the malignant cells are restricted to the
bone marrow, where interactions with the stromal niche are
thought to be critical for their survival (Hideshima et al., 2007)
and for drug resistance to traditional chemotherapy drugs
(Meads et al., 2008). The ability to overcome resistance factors
from bone marrow stromal cells (BMSCs) is now considered an
obligate requirement for any novel therapeutic agent against
MM (Dalton and Anderson, 2006). Agents like bortezomib, thalid-
omide, and lenalidomide overcome BMSC resistance in vitro
(Hideshima et al., 2000, 2001) and achieve complete, durable re-
sponses in vivo, resulting in greatly improved survival (Hideshima
et al., 2007). McMillin and colleagues used an assay in which
labeled MM cell lines are co-cultured with BMSCs and deter-
mined that the anti-MM activities of a variety of FDA-approved
and bioactive compounds are attenuated by BMSCs (McMillin
et al., 2010). We adapted this BMSC-MM co-culture assay in
384-well plates for high-throughput screening to identify com-
pounds that overcome the stroma-induced drug-resistance
phenotype in MM. Because hematological toxicity is common
for anti-MM agents, we prioritized compounds with selectivity
over human hematopoietic progenitors to identify those with
improved toxicity profiles. One such compound, BRD9876,
was discovered to be a distinctive kinesin-5 (Eg5; kinesin spindle
protein; KIF11) inhibitor that specifically targets microtubule-
bound Eg5, allowing greater selectivity over hematopoietic
cells. An Eg5 inhibitor, ARRY-520, is showing promising, durable
responses in MM (Shah et al., 2011), but its use is limited by he-
matological toxicity. We report here a novel mechanism of Eg5
inhibition that could preserve anti-MM efficacy while mitigating
potentially life-threatening hematological toxicity during MM
treatment.
RESULTS
Screening for Compounds that Overcome Stromal
Resistance in Multiple Myeloma
To recapitulate the MM niche in vitro, we used primary human
BMSCs isolated from hip replacement samples, removed for
non-cancerous indications. We co-cultured primary MM cells
with these BMSCs and stained them with the vital dye Calcein
AM, utilizing intensity and shape differences to distinguish and(D) Stroma confers drug resistance to dexamethasone.MM1S-GFP cells were exp
for 3 days in the presence (green) or absence (black) of stroma and quantified b
(E) Viability measurements by imaging are equivalent to the Cell-Titer-Glo reagen
vorinostat for 3 days, following which remaining viable cells were quantified by
content. Data are avg ± SEM (n = 2).
Cequantify the two cell types in the MetaXpress software (Molecu-
lar Devices). Primary MM cells displayed round, bright staining
(Figure 1A), whereas BMSCs alone appeared as dull, spindle-
shaped objects. Co-culture with BMSCs maintained the viability
of CD138(+) primary MM cells >5-fold better than culture media
alone (Figure 1B), confirming previously observed stroma de-
pendence of primary MM (Zlei et al., 2007). To recapitulate this
behavior in a cell line amenable to high-throughput screening,
the stroma-dependent MM cell line MOLP5 (Matsuo et al.,
2000), stably expressing GFP, was similarly grown alone or in
co-culture with stroma in 384-well plates. A similar 7-fold in-
crease in GFP(+) MOLP5 cells was observed with stromal co-
culture (Figure 1B) using image-based quantification, making
this an attractive physiologically relevant high-throughput assay
to screen for small-molecule inhibitors of MM within its niche.
To determine the impact of stroma on the activity of small mol-
ecules, we chose two other MM cell lines (MM.1S cells and IL6-
dependent INA6 cells) that grow with or without BMSCs. MM.1S
(MM1S) cells grow well alone but double their proliferation in the
presence of stromal cells (Hideshima et al., 2001; Figure 1C). The
survival of INA6 cells is dependent on the presence of high con-
centrations of IL6 or on co-culture with BMSCs (Chatterjee et al.,
2002). The effect of BMSC co-culture on small-molecule activity
was confirmed in these cells. Dexamethasone inhibited the
growth of MM1S grown alone, but not in the presence of stroma
(Figure 1D). In contrast, bortezomib, which overcomes microen-
vironment resistance (Hideshima et al., 2001), is equally active in
the presence or absence of stroma, consistent with its ability to
induce durable complete responses in vivo. Thus, small mole-
cules that overcome stromal resistance can be identified using
MM1S and INA6 cells with or without stromal co-culture.
Assay optimization was achieved using vorinostat as a positive
control. The image-based viability assay and the Cell-Titer-Glo
assay (Promega;measures cellular ATP content) produced similar
dose-response curves (Figure 1E) with vorinostat. The Z’ factor,
a statistical test of assay robustness that incorporates SDs
and differences ofmeans of negative and positive controls (Zhang
et al., 1999), was consistently above 0.5 for the MOLP5-BMSC
imaging assay, confirming its suitability for high-throughput
screening.
We chose the MOLP5-BMSC co-culture assay as the primary
assay for screening small molecules to identify compounds that
either overcome stromal resistance or are active against stroma-
dependent MM. A library of 25,280 compounds comprising
FDA-approved drugs, bioactive compounds, natural products,
commercial vendor compounds, kinase-biased compounds,
chromatin-biased compounds, and compounds synthesized at
the Broad Institute using diversity-oriented synthesis (DOS)
(Nielsen and Schreiber, 2008) were tested in duplicate in the pri-
mary assay and showed good reproducibility (Figure 2A). Com-
pounds that inhibited MOLP5 growth with Z scores%2 relative
to DMSO controls in both replicates were considered ‘‘hits’’.osed to varying concentrations of dexamethasone (top) or bortezomib (bottom)
y imaging. Data are avg ± SEM (n = 8).
t. MM1S-GFP cells growing alone were exposed to varying concentrations of
imaging (blue) or using the Cell-Titer-Glo reagent (black) that measures ATP
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Figure 2. High-Throughput Screen Identifies Small Molecules that Overcome Stromal Resistance
(A) Summary of screening data for both replicates of 24,320 compounds (blue) on MOLP5-GFP co-cultured with stroma, depicted as Z scores of DMSO controls
(red). Compounds with Z score < 2.0 in both replicates were considered ‘‘hits’’ (yellow).
(B) Schematic summarizing the experimental approaches used to filter high-priority compounds that overcome bone marrow stromal cell (BMSC) resistance.
Criteria used for each step are in blue, and numbers of compounds tested in each step are on the right.
(C) Structure of a hit compound BRD9647.
(D) BRD9647 is selective for stroma-dependent MM cells. MM1S-GFP (green) or stroma-dependent MOLP5-GFP (blue) and primary MM cells (orange) were
grown with stroma and exposed to eight doses of BRD9647 for 3 days and then viable cells were quantified by imaging. Data are avg ± SEM (n = 2).
(legend continued on next page)
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We developed a prioritization schema to identify compounds
of high interest (Figure 2B). We tested hits on BMSCs growing
alone to exclude compounds with non-specific toxicity. Then,
to exclude compounds that are susceptible to stromal resistance
(like dexamethasone), we tested hits at eight doses on MM1S
and INA6 cells with or without BMSCs. Compounds with IC50
with BMSCs% IC50 without BMSCs were validated by ordering
them in powder form and then retesting in primary and second-
ary assays. We identified 60 compounds that reproducibly in-
hibited MM growth, did not demonstrate non-specific toxicity,
and could overcome stromal resistance (Table S1). Because he-
matological toxicity is common for most MM inhibitors, we then
tested compounds on human CD34+ hematopoietic progenitors
growing in serum-free liquid culture media, an assay predictive
for in vivo hematological toxicity (Olaharski et al., 2009). Only a
few compounds demonstrated greater inhibition of MM growth
than hematopoietic growth (Table S1), and of these, three com-
pounds were tested on primary MM cells co-cultured with
BMSCs.
We identified compounds with unique selectivity patterns. A
sulfonamide BRD9647 (Figure 2C) displayed selective inhibition
of stroma-dependent MOLP5 and primary MM cells, but not
stroma-independent cell lines like MM1S (Figure 2D). This com-
pound suppressed the viability of three out of six primary MM
samples (Figures S1A and S1B) at greater than or equal to two
concentrations%10 mM (p < 0.05 by t test), but the maximal ef-
fect did not exceed 50% in any sample, suggesting primarily
cytostatic effects. A chromanone BRD2588 (Figure S1C) dis-
played enhanced activity in the presence of stroma (the opposite
of dexamethasone). In contrast to vorinostat (Figure S1D), a
hydrazone-containing hydroxamic acid BRD2318 displayed
selectivity for IL6-dependent INA6 (Figure S1E).
We focused our attention on a naphthalene bis-nitrile
BRD9876 (Figure 2E) that inhibited MM1S growth equally with
or without BMSCs (like bortezomib) with a modest (4-fold)
but significant selectivity over normal CD34+-derived hemato-
poietic cells (MM1S IC50: 2.2 ± 0.5 mM; CD34 IC50: 9.2 ± 2 mM;
Figure 2F). In contrast, no MM over CD34 selectivity was
observed for most tested compounds such as doxorubicin (Fig-
ure 2F), which causes significant hematological toxicity in vivo in
MM patients (Alberts and Salmon, 1975). BRD9876 was able to
overcome, in MM1S cells, stromal resistance of BMSCs from
MM bone marrow aspirates (Figure 2G), but only minimal effects
were observed with BRD9876 against primary MM cells (Fig-
ure S2A). This was initially concerning, but we observed that pri-
mary MM cells do not proliferate in vitro, even in the presence of
stroma in contrast to cell lines like MM1S (Figure S2B). Consis-
tent with the lack of proliferation, primary MM cells were insensi-
tive to the anti-mitotic Eg5 inhibitor ARRY-520 (Figure S2C),
which is efficacious against MM in vivo, although they were sen-
sitive to bortezomib that induces apoptosis (Figure S2D). These
data suggested that BRD9876 may be specific for cycling MM
cells. Because BRD9876 was able to inhibit diverse MM cell(E) Structure of another hit compound BRD9876.
(F) BRD9876 overcomes stroma resistance and spares hematopoietic progenitor
(green) and, along with cells derived from CD34+ hematopoietic progenitors (red
Viable cells were quantified by imaging (MM1S) or with Cell Titer Glo (CD34). Da
Celines, overcome stromal resistance, and display selectivity over
hematopoietic progenitors, we undertook studies to identify its
mechanism of action.
Mitotic Kinesin-5 Is the Target of BRD9876
We first synthesized or purchased structural analogs of
BRD9876 with the goal of immobilizing the compound on beads
for affinity purification of protein-binding partners. However, all
structural analogs of BRD9876 (Figure S3) were either less active
against MM1S cells or lost selectivity between MM1S and CD34
blood cells. We therefore switched our attention to under-
standing the functional effects of BRD9876 on MM1S cells.
Gene-expression analysis of MM1S cells treated for 6 hr with
BRD9876 revealed sparse changes—only ten genes changed
in expression >2-fold. Network analysis of genes with >1.5-fold
changes revealed no significant relationship between genes
(Figure S4A). We turned to analyzing individual genes, focusing
on the top downregulated gene, ID1 (Figure 3A). We queried
the Connectivity Map database (Lamb et al., 2006), which con-
tains over 7,000 gene-expression profiles of bioactive com-
pounds, for compounds that downregulate ID1 expression.
The top ten compounds that downregulate ID1 included the
anti-mitotic paclitaxel (Figure S4B). This finding, in addition to
literature reports of ID1 expression being associated with
abnormal mitoses (Man et al., 2008), suggested possible anti-
mitotic effects of BRD9876. Cell-cycle analysis of MM1S treated
with 10 mM BRD9876 revealed rapid arrest of cells at the G2/M
phase, starting as early as 2 hr of treatment (Figure 3B). In
contrast, CD34 hematopoietic cells treated with BRD9876
showed markedly less G2/M arrest (Figure 3C), albeit these cul-
tures contained fewer cycling cells.
To determine whether treated MM1S cells arrested at G2 or
entered mitosis, we stained the mitotic spindle protein a-tubulin.
Not only were a significant number of cells arrested in mitosis,
but they uniformly exhibited an aberrant mono-astral mitotic
spindle (Figure 3D). Mono-astral spindles are a characteristic
feature of inhibitors of mitotic kinesin-5 (Eg5), first demonstrated
with the Eg5 inhibitor monastrol (Mayer et al., 1999) but later
observed with polo-like kinase or aurora kinase inhibitors (Tille-
ment et al., 2009). Therefore, we tested Eg5 activity in a microtu-
bule-gliding assay in which recombinant full-length Eg5 drives
motility of rhodamine-labeled microtubules (Mayer et al., 1999).
In the presence of 1 mM BRD9876, Eg5-mediated microtubule
gliding was completely arrested (Figure 3E). Inhibition of Eg5 ac-
tivity was further confirmed in a microtubule-stimulated ATPase
assay of the recombinant Eg5 motor domain that demonstrated
that BRD9876 was an ATP non-competitive inhibitor of Eg5 (Fig-
ures 3F and S5A).
Novel BRD9876 Resistance Mutation Suggests
a Distinct Allosteric Binding Site
Eg5 inhibitors such as ARRY-520 have demonstrated promising
durable responses in MM (Shah et al., 2011), prompting as. MM1S-GFP cells were either grown alone (black) or co-cultured with stroma
), exposed to eight doses of BRD9876 (top) or doxorubicin (bottom) for 3 days.
ta are avg ± SEM (nR 6).
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Figure 3. Novel Small Molecule BRD9876 Is a Mitotic Kinesin-5 Inhibitor
(A) Affymetrix gene-expression analysis of MM1S cells treated with 10 mM BRD9876 for 6 hr compared with DMSO-treated cells identifies ID1 as the top
downregulated gene. The top ten Affymetrix probe sets downregulated by BRD9876 treatment are depicted here.
(B) Cell-cycle analysis of MM1S cells treated with DMSO (top left panel) or 10 mM BRD9876 (remaining panels) for indicated time points. Staining intensity of the
DNA stain propidium iodide (corresponding to ploidy) is depicted on the x axis and numbers of cells on the y axis.
(legend continued on next page)
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phase-III registration trial (Owens, 2013). Current clinical Eg5 in-
hibitors such as ispinesib and ARRY-520 bind the monastrol-
binding loop L5 region on Eg5 (Talapatra et al., 2012; Woessner
et al., 2009) and exhibit severe hematological toxicity (Burris
et al., 2011; Shah et al., 2011) requiring myeloid growth factor
support. Because BRD9876 exhibited selectivity between MM
and hematopoietic cells, we reasoned that BRD9876 may have
a different mode of Eg5 inhibition. To explore this, MM1S cells
were raised to be resistant to BRD9876 by serial exposure
to increasing compound concentrations. Consistent with our
reasoning, an MM1S subline, MM1S-BRD9876R, had no
cross-resistance to ispinesib (Figure 4A). Sequencing Eg5
cDNA from MM1S-BRD9876R revealed a previously unreported
heterozygousmutation (Figure 4B) that alters the amino acid res-
idue at position 104 from tyrosine (Y) to cysteine (C), suggesting
a dominant drug-resistance allele. Intriguingly, this mutation is
distant from the known binding site of existing Eg5 inhibitors
(Figure 4C), suggesting a distinct allosteric binding site for
BRD9876. Resistance to existing Eg5 inhibitors like ispinesib
and monastrol is mediated by a loop L5 mutation at position
130 aspartate (D130; Figure 4C; Luo et al., 2007). To confirm
the unique resistance mechanism of BRD9876, we generated
recombinant Eg5 motor domain constructs, containing the
wild-type (WT) sequence, Y104C mutation, or D130V mutation.
Enzymatic microtubule-stimulated ATPase activities were iden-
tical for all three constructs (Figure S5B). The Y104C mutant
was completely resistant to BRD9876 (Figure 4D) while showing
no alteration to ispinesib activity. In contrast, the D130V mutant
conferred 10-fold resistance to ispinesib and 10-fold sensiti-
zation to BRD9876. To test whether the Eg5 mutations were suf-
ficient to confer resistance in cells, we introduced lentiviral vec-
tors containing C-terminal GFP-tagged Eg5 open reading frame
(ORF) with the WT sequence or Y104C or D130V mutations
into adherent SW48 cells, chosen because of a high efficiency
of lentiviral transduction. Cells expressing the Y104C mutant
construct were resistant to BRD9876, consistent with the domi-
nant drug-resistant nature of this allele, whereas the D130V mu-
tation conferred enhanced sensitivity (Figures 4E). In contrast,
the D130V, but not the Y104C, construct imparted resistance
to ispinesib. Similar results were obtained using doxycycline-
inducible lentiviral constructs in MM1S cells (Figure S5C).
A recent report described a distinct Eg5 allosteric binding site
between the a4 and a6 helices using a benzimidazole compound
BI8 (Ulaganathan et al., 2013; Figure S5D). BI8 also bound, with
weaker affinity, a site partially overlapping with the ispinesib L5
site. The crystal structure demonstrates that the Y104 residue
participates in BI8 binding, forming a face-to-face stacking inter-
action with the trifluoromethylbenzyl group (Figure S5E). Indeed,(C) Cell-cycle analysis of CD34+ cells cultured for 6 days and then treated with e
(D) Mono-astral mitotic pattern of MM1S cells treated with 10 mM BRD9876 for 4
33342 is blue.
(E) Effect of BRD9876 on the gliding of rhodamine-labeledmicrotubules on immob
Images from a time-lapse sequence taken at indicated time points show that t
BRD9876 (right). The scale bar represents 2 mm.
(F) BRD9876 is an ATP non-competitive Eg5 inhibitor. ATPase activity of rec
concentrations of ATP with/without increasing concentrations of BRD9876. The
x axis, suggesting ATP non-competitive mode of inhibition. Data are avg ± SEM
Cebiochemical ATPase assays confirmed that the Y104C mutation
conferred resistance to BI8 activity (Figure S5F). In contrast to
BRD9876, neither the Y104C or D130V mutants imparted resis-
tance to BI8 in cells expressing those constructs (Figure S5G),
suggesting that BI8 occupies both allosteric sites at the higher
concentrations required for cellular growth inhibition. These
studies confirm that the Y104 residue is a bona fide member of
the a4/a6 allosteric site and that BRD9876 binds exclusively to
this site.
BRD9876 Specifically Inhibits Microtubule-Bound
Kinesin-5
The Eg5 motor domain has basal ATPase activity in the absence
of microtubules, but it is 100-fold less efficient (Luo et al.,
2004). Surprisingly, we found that BRD9876 was completely
ineffective at inhibiting the basal ATPase activity of Eg5, in
contrast to loop-L5-binding monastrol or a4/a6-binding BI8 (Fig-
ure 5A), which showed greater activity against basal Eg5 ATPase
activity.
To determine whether BRD9876 is selective for microtubule-
bound Eg5 within cells, we altered the levels of microtubule-
bound protein. Association of Eg5 with microtubules is regulated
by CDK1-mediated phosphorylation of Eg5 threonine 927
(Blangy et al., 1995). CDK1 activity in turn is negatively regulated
by the tyrosine kinase WEE1 and treatment with MK1775, a se-
lective WEE1 inhibitor, forces CDK1 activation (Krajewska
et al., 2013). MM1S cells treated withMK1775 showed increased
levels of a faster migrating band (Figure 5B) in immunoblots with
three different antibodies specific for threonine-927-phosphory-
lated Eg5 (phospho-Eg5) or the carboxy terminus (C-terminal
Eg5) or amino terminus of Eg5 (N-terminal Eg5), confirming that
the band contained full-length Eg5. The intensification of the
lower band with increasing doses of MK1775 was markedly
higher with the phospho-Eg5-specific antibody (Figure S6A),
suggesting that this band primarily contains phospho-Eg5. The
upper band showed a smaller increase in intensity caused by
MK1775 treatment, suggesting that it contains only a minority
of phospho-Eg5. The phospho-Eg5 antibody was confirmed to
recognize phosphorylated Eg5 using phosphatase treatment,
which reduced recognition of both bands by the phospho-Eg5
antibody, but not the C-terminal Eg5 antibody (Figure S6B).
Electrophoretic mobility shifts can occur due to conformational
changes, resulting in altered detergent binding in various pro-
teins including Eg5 (Kim et al., 2010; Rath et al., 2009). The faster
migrating electrophoresis pattern observed in Figure 5B may
thus reflect conformational changes caused by forced CDK1-
mediated Eg5 phosphorylation. Consistent with greater levels
of phosphorylated, microtubule-bound Eg5, MK1775-pretreatedither DMSO (top) or 10 mM BRD9876 (bottom) for 24 hr.
hr. The mitotic spindle protein a-tubulin is red, and DNA stained with Hoechst
ilized kinesin-5 (Eg5) tetramers. A schematic of the assay is depicted at the top.
etrameric Eg5 drives microtubule gliding with DMSO (left), but not with 1 mM
ombinant Eg5 motor domain (residues 1–368) was measured with varying
double reciprocal (Lineweaver-Burke) plots have a common intercept on the
of 6.
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Figure 4. BRD9876 Has a Unique Mode of Resistance
(A) MM1S cells raised to be resistant to BRD9876 are not cross-resistant to an existing Eg5 inhibitor ispinesib. BRD9876-resistant MM1S cells
(MM1S-BRD9876R; red) or parental MM1S cells (black) were exposed to varying doses of BRD9876 (top) or ispinesib (bottom) for 3 days. Data are avg ± SEM
(n = 3).
(B) BRD9876-resistant cells contain a novel heterozygous mutation. Eg5-coding region was PCR amplified from cDNA of MM1S-BRD9876R or MM1S cells and
sequenced with traditional Sanger sequencing. A heterozygous missensemutation c.311A/G, p.Tyr104Cys (Y104C) was found in resistant cells (top), but not in
parental sensitive cells (bottom).
(C) X-ray crystal structure of the Eg5motor domain bound to ispinesib (fromPDB 4AP0), indicating that Y104 (yellow) is distant from the ispinesib-binding site. The
D130 residue, mutations of which result in resistance to ispinesib, is also highlighted in yellow.
(D) Y104C mutation causes resistance to BRD9876, but not ispinesib, in Eg5 ATPase assays. Recombinant Eg5 motor domain (residues 1–368) proteins
containing the wild-type sequence (black), the Y104C mutation (red), or the D130V mutation (blue) were incubated with microtubules and ATP for 10 min, in the
(legend continued on next page)
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MM1S cells showed 3-fold lower IC50 to BRD9876 (Figure 5C),
whereas monastrol and BI8 activities were unchanged. The
enhanced cytotoxic activity was paralleled by an 3-fold lower
BRD9876 EC50 for mitotic arrest in MK1775-co-treated MM1S
cells (Figure 5D). The highly potent loop-L5-binding ispinesib
also preferentially binds microtubule-free Eg5 (Lad et al., 2008)
and, similar to monastrol, did not display changes in cytotoxicity
(Figure S5C) or ability to induce mitotic arrest (Figure S5D) in
MK1775-pretreated MM1S cells. Opposite effects on BRD9876
cytotoxic (Figure S5E) and mitotic (Figure S5F) activities were
observed with the CDK1 inhibitor RO3306 (Vassilev et al.,
2006). Similar shifts in BRD9876 cytotoxicity were observed
in WSU-DLCL2 lymphoma cells induced to have higher (Fig-
ure S5G) or lower (Figure S5H) levels of phospho-Eg5. These
studies supported the unique specificity of BRD9876 for phos-
phorylated, microtubule-bound Eg5.
BRD9876 Exhibits Improved Selectivity over
Hematopoietic Progenitors
Having uncovered a distinct mode of Eg5 inhibition by BRD9876,
we investigated whether BRD9876 has unique MM versus he-
matopoietic selectivity. Indeed, BRD9876 exhibited approxi-
mately 3-fold selectivity for MM1S myeloma cells (IC50 3.1 ±
0.7 mM) over CD34+-derived hematopoietic cells (9.1 ± 2 mM),
whereas the a4/a6-binding BI8 exhibited greater inhibition of
CD34 cells (24.7 ± 1 mM) than MM1S cells (57.6 ± 11.2 mM; Fig-
ure 6A). The loop-L5-binding inhibitors likewise inhibited CD34
growthmore thanMM1S cells including the low-potencymonas-
trol (CD34: 28.9 ± 5.0 mM; MM1S: 143.6 ± 101 mM) and the high-
potency ispinesib (CD34: 4.5 ± 1.0 nM; MM1S: 12.6 ± 2.1 nM).
ARRY-520, which is currently in clinical trials for treating MM,
binds the loop L5 region (Woessner et al., 2009), and like ispine-
sib and monastrol, ARRY-520 inhibited CD34 growth more
potently (IC50 1.3 ± 0.4 nM) than MM1S cells (4.9 ± 0.2 nM),
consistent with the severe hematological toxicity observed in
MM patients treated with ARRY-520 (Shah et al., 2011). On the
other hand, the ATP-competitive Eg5 inhibitor, GSK1, preferen-
tially inhibits themicrotubule-bound form of Eg5 (Luo et al., 2007)
like BRD9876 and displayed similar potencies of growth in-
hibition for both CD34 and MM1S cells. Greater selectivity for
MM1S cells was likely not observed because these cells contain
>10-fold greater ATP levels than CD34 cells, measured by the
Cell Titer Glo assay.
We verified these selectivity patterns of BRD9876 and ispine-
sib on a panel of MM and lymphoma cell lines compared with
CD34 cells (Figure 6B). Whereas the majority of tested cancer
cell lines were less sensitive than CD34 cells to ispinesib’s cyto-
toxicity, all cell lines had greater sensitivity to BRD9876 than
CD34 cells. Other MM cell lines AMO-1 and KMS11 also ex-
hibited G2/M arrest with BRD9876 treatment, confirming the
same mechanism of action against these cell lines (Figure S7A).
Altogether, ATP non-competitive inhibition of microtubule-presence of varying concentrations of BRD9876 (top) or ispinesib (bottom), an
experiments).
(E) Y104C mutation is sufficient to confer resistance to BRD9876. SW48 cells wer
Eg5 open reading frame with the WT sequence (black), Y014C mutation (red), or D
for 3 days. Cells expressing GFP-tagged Eg5 were quantified by MetaXpress. D
Cebound Eg5 by BRD9876 exclusively allowed selective inhibition
of myeloma over CD34 cells.
We determined whether BRD9876’s selectivity was due to
different growth rates of cancer cell lines and hematopoietic
cells. CD34+ cells were co-cultured with OP9 stromal cells that
are known to markedly increase growth rates of these cells (Feu-
gier et al., 2005). After 9 days, OP9-co-cultured hematopoietic
cells were >10-fold greater than cells grown alone in cytokine-
supplemented media (Figure S7B). However, this increase in
growth rate was not accompanied by an increase in sensitivity
to 3 days of BRD9876 exposure (Figure S7C). We next deter-
mined whether subpopulations of hematopoietic cells had differ-
ential sensitivity to BRD9876 using immuno-phenotyping. After
3 days of exposure to BRD9876, there was a slight enrichment
of CD34+ cells (16%–22.5%) and a slight decrease in cells
weakly expressing myeloid markers (from 26.4% to 14.6%) but
no change in cells expressing erythroid markers or cells strongly
expressing myeloid markers (Figure S7D). Few cells (<5%) ex-
pressed megakaryocytic markers (CD41) or lymphoid markers
(CD3 and CD19) and were not analyzed.
In these experiments, hematopoietic progenitors were grown
in serum-free liquid culturemedia for ease of handling, compara-
bility to MM cell line growth-inhibition assays, and amenability to
high-throughput testing. ‘‘Gold standard’’ assays tomeasure he-
matopoietic toxicity are colony-forming assays in semi-solidme-
dia that are predictive of drug doses causing myelosuppression
in vivo (Parchment et al., 1998). Doses that cause dose-limiting
neutropenia in vivo are correlated to IC90 concentrations in gran-
ulocyte-macrophage colony-forming unit (CFU-GM) assays
in vitro (Pessina et al., 2003). We tested BRD9876 and ispinesib
on colony formation of CD34+ progenitors grown in cytokine-
supplemented methylcellulose media (Figure 7A), and dose-
response relationships were found to be comparable to CD34
cells grown in liquid culture (Figure 6A). Whereas BRD9876
began suppressing erythroid colonies (BFU-E) at 10 mM, sup-
pression of myeloid (CFU-GM) colonies was only noted at
20 mM. These data suggest that concentrations of BRD9876
that suppressMMcell line growth (2–10 mM) are unlikely to cause
significant myeloid toxicity (neutropenia) in vivo.
Finally, we determined whether phospho-Eg5 levels, which
are associated with BRD9876 activity, are different between
MM and hematopoietic cells. Indeed, cultured MM1S myeloma
cells had 3-fold higher levels of phospho-Eg5 than cultured
CD34 cells (Figures 7B and 7C). Similar differences were found
between other cultured MM cell lines and CD34 cells (Fig-
ure S7E). To exclude the possibility that these differences arose
because of the different culture conditions of the two cell types,
we tested uncultured CD138+ primary MM cells or CD34+ he-
matopoietic progenitors isolated from human bonemarrow aspi-
rates. Even larger differences (10-fold) in phospho-Eg5 levels
were found between these uncultured MM and hematopoietic
cells (Figures 7B and 7C). We tested a larger panel of differentd ATP consumption by Eg5 was quantified. Data are avg ± SEM of 6 (three
e transduced with pLX-TRC312 lentiviruses containing C-terminal GFP-tagged
130V mutation (blue) and then exposed to BRD9876 (top) or ispinesib (bottom)
ata are avg ± SEM of 4 (two experiments).
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Figure 5. BRD9876 Inhibits Only Microtubule-Bound Eg5
(A) BRD9876 is only active against microtubule-bound Eg5. ATPase activity of Eg5 motor domain was measured in the presence (black) or absence (red) of
microtubules with BRD9876 (top), monastrol (middle), or BI-8 (bottom). Data are avg ± SEM (n = 4).
(B) Eg5 phosphorylation can be increased by using aWEE1 inhibitor. Top: schematic showing howMK1775’s inhibition of WEE1 releases inhibition of CDK1, thus
increasing Eg5 phosphorylation. Bottom: MM1S cell lysates treated with DMSO or increasing doses of MK1775 for 24 hr were resolved on a 3%–8% tris-acetate
gel and immunoblotted with antibodies recognizing Thr927 phosphorylated Eg5 (top), Eg5 C-terminal (middle), Eg5 N-terminal (bottom), or a-tubulin (far bottom).
Images were acquired with the LI-COR Odyssey CLX system. A faster migrating band, visible with all three antibodies, intensifies with increasing MK1775 doses
and likely represents phospho-Eg5.
(legend continued on next page)
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patient-derived CD138+ primary MM cells compared with
CD34+ hematopoietic progenitors from different healthy donors
(Figure 7D). In all comparisons, the phospho-Eg5 band was
consistently higher in freshly isolated MM cells than hematopoi-
etic progenitors, indicating that elevated phospho-Eg5 occurs
in vivo in MM cells and is conserved across different MM cell
types and altogether suggesting that the mode of Eg5 inhibition
by BRD9876 may have a significant therapeutic index in vivo.
DISCUSSION
In this study, we used the clinically desirable phenotypes of over-
coming stromal resistance in multiple myeloma and sparing he-
matopoietic progenitors and identified a distinct mechanism of
Eg5 inhibition. A phenotypic approach identified the first Eg5 in-
hibitor monastrol and revealed its target Eg5 as a viable thera-
peutic target (Mayer et al., 1999). This led to the development
of a number of Eg5 inhibitors, and one such inhibitor ARRY-
520 is now in phase III trials against MM (Owens, 2013). ARRY-
520 leads to durable responses in MM patients (Shah et al.,
2011), suggesting that this class of inhibitors can overcome stro-
mal resistance. This is likely because very little signal transduc-
tion occurs during mitosis from the cell surface to the nucleus
(as evidenced by the sparse transcriptional changes induced
by BRD9876 in Figure S4A), therefore making it difficult for can-
cer cells arrested in mitosis to turn on survival pathways using
external stromal signals. Existing Eg5 inhibitors are clinically
limited by severe (grade 3 or 4) neutropenia (Burris et al., 2011;
Shah et al., 2011), and it was not known until this report whether
this toxicity could be mitigated. Using the phenotype of sparing
hematopoietic cells, we uncovered a unique mode of Eg5 inhibi-
tion through the binding of BRD9876 to a distinct allosteric site
on phosphorylated, microtubule-bound form of Eg5. Human he-
matopoietic cells are relatively spared in this approach, likely
because they contain less phosphorylated (microtubule-bound)
Eg5. Conversely, greater proportions of unphosphorylated
(non-microtubule-bound) Eg5 in hematopoietic cells may in-
crease their susceptibility to current inhibitors such as monas-
trol, ispinesib, and ARRY-520 (Figure 6A), which preferentially
inhibit the free form of Eg5 (Lad et al., 2008; Luo et al., 2004).
Hence, inhibition of the same target can have different selectivity
outcomes depending on the mode of inhibition.
There are three features unique to BRD9876’s inhibition of Eg5
activity: (1) interaction with the tyrosine 104 residue that is part of
the a4-a6 allosteric binding pocket; (2) microtubule-dependent
inhibition; and (3) ATP non-competitive inhibition. Benzimid-
azole-8 binds the a4-a6 pocket (Ulaganathan et al., 2013) but
preferentially inhibits the free form of Eg5 (Figure 5A) and dis-
plays greater toxicity toward hematopoietic cells (Figure 6A).
ATP-competitive inhibitors of Eg5 like GSK1 (Luo et al., 2007)
that bind the a4-a6 pocket are specific for microtubule-bound
protein but do not inhibit MM1S cells more potently than CD34
cells (Figure 6A), likely because MM cells contain higher levels(C) Increasing Eg5 phosphorylation by MK1775 pretreatment only enhances BRD
24 hr and then treated with BRD9876 (top), monastrol (middle), or BI-8 (bottom) fo
(D) Increasing Eg5 phosphorylation enhancesmitotic arrest by BRD9876.MM1S c
24 hr were stained for the mitotic marker phospho-histone H3 (S10). Data are av
Ceof ATP. We are unaware of any inhibitor of Eg5 with the unique
properties of BRD9876 thus far (although a wide variety of Eg5
inhibitors have been developed by pharmaceutical companies;
El-Nassan, 2013). BRD9876 is a tool compound and is not likely
to be a drug candidate, given its simple structure and lack of me-
dicinal chemistry opportunities for optimization (Figure S3). It is
important to recognize that a number of additional steps (medic-
inal chemistry to optimize physicochemical properties, phar-
macokinetic analyses, in vivo efficacy testing, comprehensive
toxicity profiling, etc.) are required before a compound with
BRD9876’s mechanism of action can be a therapeutic can-
didate. But just as the tool compound monastrol led to the de-
velopment of optimized loop-L5-binding drug candidates like
ispinesib and ARRY-520, our findings indicate that a new gener-
ation of Eg5 drug candidates with BRD9876-like mechanism of
action should be developed and prioritized for clinical testing
based on their potential for lower hematological toxicity.
We noted that hematological toxicities were not reported in
murine xenograft studies describing the use of Eg5 inhibitors
like ispinesib and ARRY-520 (Purcell et al., 2010; Woessner
et al., 2009), even though the dose-limiting toxicity for these
and other Eg5 inhibitors is severe (grade 4) neutropenia in human
studies (Burris et al., 2011; Shah et al., 2011). This is likely
becausemurine hematopoietic cells are generally more resistant
than human hematopoietic cells to commonly used anti-cancer
drugs (that cause neutropenia in humans) with distinct mecha-
nisms such as irinotecan (Erickson-Miller et al., 1997), paclitaxel
(Kurtzberg et al., 2009), and fludarabine (Bagley et al., 2009). We
therefore deprioritized testing BRD9876 in murine models
because it would be difficult to demonstrate the advantage
of BRD9876 in sparing hematopoietic progenitors in murine
models. Instead, we demonstrated that, unlike other Eg5 inhibi-
tors, efficacious doses of BRD9876 spare human hematopoietic
progenitors in the CFU-GM assay (Figure 7A), which is more pre-
dictive of human hematological toxicity (Parchment et al., 1998;
Pessina et al., 2003). Altogether, Eg5 inhibitors with BRD9876-
like mechanisms of action may display a greater therapeutic
index (difference between efficacious and toxic doses) than ex-
isting Eg5 inhibitors in human studies, but not in preclinical xeno-
graft models.
The advantage of improving the therapeutic index of Eg5 in-
hibitors can be inferred from promising clinical trial results of
ARRY-520 in MM. Because neutropenia was the dose-limiting
toxicity early in phase I testing, patients were treated with gran-
ulocyte colony-stimulating factor (G-CSF) support that boosts
neutrophil counts (Shah et al., 2011). This allowed a higher
maximal tolerated dose to be administered to patients and
longer durations of treatment. Clinical investigators reported
that the median time to response with ARRY-520 was noticeably
prolonged (3.7 months; Shah et al., 2011), consistent with the
primarily cytostatic effects of Eg5 inhibition. In most clinical
trials with Eg5 inhibitors in which G-CSF support was not used,
treatment durations were short, which may have precluded9876’s cytotoxic activity. MM1S cells were pretreated with 0.5 mMMK-1775 for
r 3 days. Data are avg ± SEM (nR 4; greater than or equal to two experiments).
ells co-treatedwith 0.5 mMMK1775 and varying concentrations of BRD9876 for
g ± SEM (n = 4).
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Figure 6. BRD9876 Exhibits Improved Selectivity between Myeloma Cells and Hematopoietic Progenitors
(A) BRD9876 has unique selectivity for MM over hematopoietic cells. MM1S cells (black) and CD34+-derived hematopoietic cells (red) were exposed to various
concentrations of BRD9876 (top left), BI-8 (top right), monastrol (middle left), ispinesib (middle right), ARRY-520 (bottom left), or GSK-1 (bottom right) for 3 days
and then viability measured with Cell Titer Glo. Data are avg ± SEM (nR 4; greater than or equal to two experiments).
(B) Improved cancer/normal selectivity with BRD9876. The indicated MM cell lines (gray), lymphoma cell lines (blue), or normal hematopoietic cells (red) were
exposed to BRD9876 (left) or ispinesib (right) for 3 days and then viability was measured with Cell Titer Glo. Data are avg ± SEM (nR 6; greater than or equal to
three experiments).demonstration of responses resulting from Eg5 inhibition. For
example, in a recent phase II trial of the Eg5 inhibitor AZD4877
in urothelial cancers (Jones et al., 2013), the median treatment
duration was only 43 days (1.5 months) and no responses
were noted. Because lowering neutropenia allowed higher
doses, greater treatment duration, and the demonstration of ef-
ficacy with ARRY-520, further lowering of neutropenia with the766 Cell Reports 10, 755–770, February 10, 2015 ª2015 The Authorsspecific mode of Eg5 inhibition we identified (combined with
G-CSF support) has the potential to improve further outcomes
of patients treated with this approach.
An additional discovery resulting from our study is the consis-
tently higher proportion of phospho-Eg5 in MM cells, particularly
in various types of patient-derived CD138+ cells, compared to
non-malignant hematopoietic progenitors. Whereas the simplest
Figure 7. BRD9876 Spares Colony Formation of Hematopoietic Progenitors, which Contain Lower Phosphorylated Eg5 Than Myeloma Cells
(A) CD34+ hematopoietic progenitors were cultured for 14 days in serum-free semi-solid methylcellulose media supplemented with erythroid andmyeloid growth
factors (Methocult H4436) in the presence of BRD9876 (left) or ispinesib (right). Erythroid (CFU-E) andmyeloid (CFU-GM) colonies were then quantified bymanual
counting. Data are avg ± SEM (n = 4; two experiments).
(B) MMcells have higher phosphorylated Eg5 than hematopoietic cells. Lysates of equal numbers of culturedMM1S cells, CD34+ hematopoietic cells cultured for
7 days, uncultured CD34+ cells, or uncultured CD138+ MM cells from a patient were subjected to immunoblotting for Thr927-phosphorylated Eg5, total Eg5, or
a-tubulin using chemiluminescence detection. Arrow indicates the faster migrating phospho-Eg5 band.
(C) Quantification of intensities of the faster migrating phospho-Eg5 band and its physiological substrate a-tubulin from (B) was done using Kodak Carestream
software and expressedas ratios of phospho-Eg5/a-tubulin. Datawere normalized toMM ratios for each condition (culturedMM1Sor unculturedCD138+MMcells).
(D) Differences in phosphorylated Eg5 between primaryMMand hematopoietic cells are generalizable. Equal numbers of primary CD138+ cells fromMMpatients
or CD34+ cells from healthy donors (Lonza) were compared in immunoblots for phospho-Eg5 (top) or a-tubulin (bottom) using either LI-COR fluorescence
detection (left and middle panels) or chemiluminescence (right panel). Arrow indicates the phospho-Eg5 band.
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explanation is a higher growth fraction of MM cells, increasing
the growth rate of hematopoietic cells did not affect sensitivity
to BRD9876 (Figure S7C). Furthermore, the mitotic rate of MM
cells in patients is not high, as evidenced by the limited efficacy
of microtubule-targeting anti-mitotic drugs like paclitaxel in MM
(Dimopoulos et al., 1994). It is possible thatMMcells have greatly
activated CDK1 (CDC2), which phosphorylates Eg5, beyond
physiological levels of mitotic activation. Chromosomal abnor-
malities are universal in MM (Zandecki et al., 1996), and chromo-
somal instability can cause excessive activation of the spindle
assembly checkpoint, which is known to occur in MM (Decaux
et al., 2008). Sustained spindle assembly checkpoint causes
prolonged stabilization of cyclin B, the activating partner of
CDK1 (Musacchio and Salmon, 2007). Thus, excessive CDK1
activation could occur commonly in MM, leading to high phos-
pho-Eg5, which can be selectively exploited by BRD9876.
In summary, our study has identified small molecules that
overcome the stromal resistance phenotype in MM. These small
molecules will be critical to uncover additional ‘‘druggable’’ vul-
nerabilities within MM. This phenotypic chemical-biology ap-
proach complements current genetic approaches of discovering
new therapeutic strategies against multiple myeloma, hopefully
leading us closer to the eradication of this disease.
EXPERIMENTAL PROCEDURES
All experimental procedures are described in detail in Supplemental
Information.
Cell Culture and Screening
MM cell lines MM.1S, INA6, and MOLP5 were grown in RPMI media supple-
mented with 10% fetal bovine serum and grown alone (MM.1S) with 2 ng/ml
IL6 (INA6) or in co-culture with primary human BMSCs (MOLP5). For identifi-
cation in co-cultures, these MM cell lines were stably transduced with a
GFP-expressing lentivirus. Frozen CD34+ human bone marrow hematopoietic
progenitors (Lonza) were cultured in serum-free HPGM medium (Lonza)
supplemented with 50 ng/ml thrombopoietin, 50 ng/ml FLT3 ligand, and
25 ng/ml Stem Cell Factor. Cells derived from CD34+ cells were used for ex-
periments 1 week after thawing.
For primary screening, GFP-labeled MOLP5 cells were co-cultured with un-
labeled BMSCs in 384-well plates for 2 days and then exposed to compounds
at a single concentration (10 mM) in duplicate or DMSO controls for 3 days. Re-
maining GFP(+) MOLP5 cells were quantified by high-throughput microscopy
(IXMicro; Molecular Devices), counting GFP(+) cells with the MetaXpress soft-
ware (Molecular Devices). For counter-screening, BMSCs alonewere exposed
to hit compounds at 10 mM for 3 days and viability measured using Cell Titer
Glo reagent (Promega). In secondary assays, GFP(+) MM1S or INA6 cells
were grown alone or co-cultured with BMSCs in 384-well plates and exposed
to eight doses of compounds for 3 days followed by image-based quantifi-
cation. For validation, compoundswere ordered in dry powder form from com-
mercial vendors, re-dissolved in DMSO, and re-tested on growth inhibition
assays. For tertiary screening, compounds at eight doses were tested on
CD34 hematopoietic cells for 3 days and viability measured using Cell Titer
Glo. For final validation, primary MM cells were isolated from bone marrow as-
pirates using CD138 immunomagnetic selection, co-cultured with primary
BMSCs, and exposed to eight doses of compounds for 3 days. Viable cells
were quantified using 2 mM Calcein AM staining and imaging.
Gene Expression Analysis
MM1S cells were exposed to either 10 mM BRD9876 or DMSO for 6 hr,
following which RNA was extracted using the TRIzol reagent (Invitrogen).
Hybridization on Affymetrix human U133 2.0 plus microarrays chips was
performed and results were analyzed with the Comparative Marker Selection768 Cell Reports 10, 755–770, February 10, 2015 ª2015 The Authorsalgorithm of GenePattern (http://www.broadinstitute.org/cancer/software/
genepattern).
Cell Cycle Analysis
MM1S or CD34 cells were exposed to 10 mM BRD9876 or DMSO, fixed with
70% ethanol, stained with propidium iodide, and analyzed with the FACSCa-
libur (BD Biosciences) instrument. Cell cycle analysis was performed with the
Watson modeling within Flowjo v7 software (Tree Star).
Eg5 Biochemical Assays
Microtubule gliding assays of full-length Eg5 were performed as previously
described (Mayer et al., 1999). To measure ATPase activity, recombinant
GST-tagged Eg5 motor domain (amino acid 1–368) proteins with the wild-
type sequence or Y104C or D130V mutations were generated. Microtubule-
stimulated ATPase activity was initially measured using the ELIPA kit (Cyto-
skeleton) in 96-well plates. In later experiments, the Eg5 ATPase assay was
performed in 384-well plates in PEM25 buffer (Luo et al., 2004) using the
ADP-Glo reagent (Promega) to detect ATP hydrolysis. ATP competition was
measured by varying concentrations of ATP (12.5–800 mM) and BRD9876 (0,
1.25, 5, and 20 mM) in Eg5 ATPase assays. Data were analyzed by double-
reciprocal Lineweaver-Burk plots, Michaelis-Menten plots, or mixed-model in-
hibition analyses all using GraphPad Prism 6.
Human Hematopoietic Progenitor Colony-Forming Cell Assays
Colony-forming assays for human bone marrow CD34+ hematopoietic pro-
genitors (Lonza) were performed using the Methocult H4436 Enriched kit
(Stem Cell Technologies) with varying concentrations of Eg5 inhibitors or
DMSO. Erythroid or granulocyte colonies formed after 14 days were manually
counted with a 43 objective and 60-mm gridded scoring dish.
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